Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Sage Therapeutic Com (NQ: SAGE ) 7.220 UNCHANGED Streaming Delayed Price Updated: 4:00 PM EDT, Sep 30, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings All News about Sage Therapeutic Com < Previous 1 2 3 4 5 6 7 8 9 ... 11 12 Next > 5 Biotech stocks tapping into unmet mental health treatment needs December 20, 2023 Here are five biotech companies currently working on drug candidates that tap into this soaring need for life-saving mental health treatments. Via MarketBeat ZURZUVAE™ (zuranolone) CIV, a Landmark Oral Treatment for Women with Postpartum Depression (PPD), is Now Available in the U.S. December 14, 2023 From Sage Therapeutics, Inc. Via Business Wire ZURZUVAE™ (zuranolone) CIV, a Landmark Oral Treatment for Women with Postpartum Depression (PPD), is Now Available in the U.S. December 14, 2023 From Biogen Inc. Via GlobeNewswire The Latest Analyst Ratings for Sage Therapeutics December 12, 2023 Via Benzinga Analyst Ratings for Sage Therapeutics November 08, 2023 Via Benzinga Why Sage Therapeutics Stock Sank Today November 07, 2023 A secondary stock sale and underwhelming quarterly results sent investors to the off-ramp. Via The Motley Fool The Latest Analyst Ratings for Sage Therapeutics October 13, 2023 Via Benzinga Sage Therapeutics to Present at Upcoming November Investor Conferences November 08, 2023 From Sage Therapeutics, Inc. Via Business Wire Why Sanmina Shares Are Trading Lower By Around 15%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session November 07, 2023 Gainers PaxMedica, Inc. (NASDAQ: PXMD) shares climbed 173.8% to $8.35. PaxMedica announced the publication of its autism spectrum disorder Phase 2 study results in the Annals of General Psychiatry. Via Benzinga Where Sage Therapeutics Stands With Analysts September 07, 2023 Via Benzinga Earnings Scheduled For November 7, 2023 November 07, 2023 Companies Reporting Before The Bell • CorEnergy Infr Tr (NYSE:CORR) is estimated to report earnings for its third quarter. Via Benzinga Sage Therapeutics Announces Third Quarter 2023 Financial Results and Highlights Pipeline and Business Progress November 07, 2023 From Sage Therapeutics, Inc. Via Business Wire Sage Therapeutics to Report Third Quarter 2023 Financial Results on Tuesday, November 7, 2023 October 24, 2023 From Sage Therapeutics, Inc. Via Business Wire Sage Therapeutics Announces U.S. Food and Drug Administration Granted SAGE-718 Orphan Drug Designation for the Treatment of Huntington’s Disease October 18, 2023 From Sage Therapeutics, Inc. Via Business Wire 10 Health Care Stocks With Whale Alerts In Today's Session September 08, 2023 Via Benzinga 3 Healthcare Stocks to Sell in September Before They Crash & Burn September 06, 2023 The prognosis for these healthcare stocks isn't optimistic so plan to sell them this month before they get worse. Via InvestorPlace Sage Therapeutics to Present at Upcoming September Investor Conferences September 06, 2023 From Sage Therapeutics, Inc. Via Business Wire Bragar Eagel & Squire, P.C. Is Investigating DigitalOcean, and Sage and Encourages Investors to Contact the Firm September 01, 2023 From Bragar Eagel & Squire Via GlobeNewswire INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Sage Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm September 01, 2023 Via ACCESSWIRE Sage Therapeutics Cuts Workforce By 40% Following Rejection In Depression Treatment August 31, 2023 The company is now focusing on its launch in postpartum depression. Via Investor's Business Daily Sage Therapeutics Implements Strategic Reorganization to Support Plans for ZURZUVAE™ Commercial Launch and Pipeline Advancement August 31, 2023 From Sage Therapeutics, Inc. Via Business Wire Bragar Eagel & Squire, P.C. Is Investigating Blink, Lovesac, and Sage and Encourages Investors to Contact the Firm August 27, 2023 From Bragar Eagel & Squire Via GlobeNewswire 3 Very Oversold Pharma Stocks to Buy Right Now August 24, 2023 Oversold pharma stocks have great total return potential. In this article, we list some of the best to buy. Via InvestorPlace Is Sage Therapeutics Stock in Trouble After Dropping 50% in a Month? August 24, 2023 The pharmaceutical company's growth prospects have taken a big hit. Via The Motley Fool SAGE ALERT: Bragar Eagel & Squire, P.C. is Investigating Sage Therapeutics, Inc. on Behalf of Sage Stockholders and Encourages Investors to Contact the Firm August 21, 2023 From Bragar Eagel & Squire, P.C. Via Business Wire SAGE INVESTIGATION ALERT: Robbins Geller Rudman & Dowd LLP Announces Investigation into Sage Therapeutics, Inc. and Encourages Investors with Substantial Losses or Witnesses with Relevant Information to Contact the Firm August 14, 2023 From Robbins Geller Rudman & Dowd LLP Via Business Wire Why Shares of Sage Therapeutics Slumped This Week August 11, 2023 The company got bad news from the FDA and saw increased losses. Via The Motley Fool Exposures Product Safety Consolidated Water, Spectrum Brands, Arco Platform, Semler Scientific And Other Big Stocks Moving Higher On Friday August 11, 2023 U.S. stocks traded mixed, with the Dow Jones gaining around 80 points on Friday. Here are some big stocks recording gains in today’s session. Via Benzinga Topics Stocks Exposures US Equities 2 Beaten-Down Stocks That Still Aren't Worth Buying August 11, 2023 These companies aren't bargains at all. Via The Motley Fool Benzinga's Top Ratings Upgrades, Downgrades For August 8, 2023 August 08, 2023 Via Benzinga < Previous 1 2 3 4 5 6 7 8 9 ... 11 12 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.